Amgen Inc.
A biotechnology company that makes medicines for serious illnesses, including the bone-strengthening drug Prolia, the cholesterol-lowering injection Repatha, and the psoriasis treatment Otezla, sold to patients and doctors worldwide. It was founded in 1980 in Thousand Oaks, California, as Applied Molecular Genetics, a name later shortened to "Amgen." Its first CEO famously ran the company from a small trailer so scientists could use the office space, and early experiments included trying to extract oil from shale and accelerate chicken growth.
Granted 174.6K
Granted 14.0K
Granted 17.0K
Granted 15.7K
Granted 15.0K
Granted 13.3K
Granted 3.3K
Granted 665
Granted 665
Granted 665
Granted 793.95
Granted 665
Granted 4.4K
Granted 2.4K
Granted 665
Granted 665
Granted 2.5K · Sold 1.2K
Granted 771.19
Granted 744.64
Granted 665
Granted 1.4K
Granted 665
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bradway Robert AChairman, CEO and President, Director · 9 transactions | — | 655.2K | 174.6K | — | — |
| Santos EstebanEVP, Operations · 7 transactions | +8.1% | 83.8K | 14.0K | — | — |
| Gordon MurdoEVP, Global Commercial Ops · 7 transactions | +22.2% | 51.2K | 17.0K | — | — |
| Griffith Peter H.EVP & CFO · 7 transactions | +18.7% | 50.1K | 15.7K | — | — |
| Reese David MEVP & Chief Technology Officer · 7 transactions | +19% | 42.3K | 15.0K | — | — |
| Graham Jonathan PEVP & Gen. Counsel & Sec. · 7 transactions | +18.5% | 39.7K | 13.3K | — | — |
| Bradner James E.EVP, Research and Development · 3 transactions | +5.9% | 30.0K | 3.3K | — | — |
| Eckert RobertDirector · 1 transaction | +4.9% | 26.3K | 665 | — | — |
| Jacks TylerDirector · 1 transaction | +6.3% | 18.3K | 665 | — | — |
| Kullman Ellen JamisonDirector · 1 transaction | +7.9% | 14.5K | 665 | — | — |
| Holley Charles MDirector · 2 transactions | +7.4% | 14.1K | 793.95 | — | — |
| Garland Greg C.Director · 1 transaction | +5% | 13.8K | 665 | — | — |
| Miller DerekSVP, Human Resources · 7 transactions | +22.1% | 12.4K | 4.4K | — | — |
| Khosla RachnaSVP, Business Development · 7 transactions | +18.5% | 8.4K | 2.4K | — | — |
| Druker BrianDirector · 1 transaction | +10.9% | 8.4K | 665 | — | — |
| Austin Wanda MDirector · 1 transaction | +9% | 8.0K | 665 | — | — |
| Grygiel Nancy A.SVP & CCO · 8 transactions | -17.1% | 7.4K | 2.5K | — | 1.2K |
| Ishrak OmarDirector · 2 transactions | +13.1% | 7.4K | 771.19 | — | — |
| Drake Michael VDirector · 2 transactions | +16.4% | 5.8K | 744.64 | — | — |
| Miles Amy EDirector · 1 transaction | +16.5% | 5.6K | 665 | — | — |
| Busch Matthew C.VP, Finance & CAO · 7 transactions | +26.9% | 4.3K | 1.4K | — | — |
| Klotman Mary E.Director · 1 transaction | +44.7% | 2.2K | 665 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -1.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.